| Current and future therapeutic approaches for osteosarcoma DJ Harrison, DS Geller, JD Gill, VO Lewis, R Gorlick Expert review of anticancer therapy 18 (1), 39-50, 2018 | 648 | 2018 |
| Advancing therapy for osteosarcoma J Gill, R Gorlick Nature reviews Clinical oncology 18 (10), 609-624, 2021 | 413 | 2021 |
| New targets and approaches in osteosarcoma J Gill, MK Ahluwalia, D Geller, R Gorlick Pharmacology & therapeutics 137 (1), 89-99, 2013 | 308 | 2013 |
| Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma P Koirala, ME Roth, J Gill, S Piperdi, JM Chinai, DS Geller, BH Hoang, ... Scientific reports 6 (1), 30093, 2016 | 258 | 2016 |
| Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma M Roth, M Linkowski, J Tarim, S Piperdi, R Sowers, D Geller, J Gill, ... Cancer 120 (4), 548-554, 2014 | 168 | 2014 |
| Osteosarcoma HC Beird, SS Bielack, AM Flanagan, J Gill, D Heymann, KA Janeway, ... Nature Reviews Disease Primers 8 (1), 77, 2022 | 137 | 2022 |
| HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival P Koirala, ME Roth, J Gill, JM Chinai, MR Ewart, S Piperdi, DS Geller, ... Scientific reports 6 (1), 31154, 2016 | 89 | 2016 |
| Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma VI Poon, M Roth, S Piperdi, D Geller, J Gill, ER Rudzinski, DS Hawkins, ... Clinical sarcoma research 5, 1-4, 2015 | 73 | 2015 |
| Targeting glycoprotein NMB with antibody‐drug conjugate, glembatumumab vedotin, for the treatment of Osteosarcoma M Roth, DM Barris, S Piperdi, V Kuo, S Everts, D Geller, P Houghton, ... Pediatric Blood & Cancer 63 (1), 32-38, 2016 | 63 | 2016 |
| Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma Y Zhang, YS Zvi, B Batko, N Zaphiros, EF O’Donnell, J Wang, K Sato, ... Scientific reports 8 (1), 14294, 2018 | 56 | 2018 |
| Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma Y Cao, M Roth, S Piperdi, K Montoya, R Sowers, P Rao, D Geller, ... PLoS One 9 (8), e106249, 2014 | 52 | 2014 |
| Detection of circulating tumor DNA in patients with osteosarcoma DM Barris, SB Weiner, RA Dubin, M Fremed, X Zhang, S Piperdi, ... Oncotarget 9 (16), 12695, 2018 | 43 | 2018 |
| Advances in therapy for pediatric sarcomas A Weiss, J Gill, J Goldberg, J Lagmay, H Spraker-Perlman, ... Current oncology reports 16, 1-11, 2014 | 36 | 2014 |
| A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: metformin with … M Trucco, JC Barredo, J Goldberg, GM Leclerc, GA Hale, J Gill, B Setty, ... Pediatric blood & cancer 65 (9), e27224, 2018 | 35 | 2018 |
| The Paf oncogene is essential for hematopoietic stem cell function and development YM Amrani, J Gill, A Matevossian, ES Alonzo, C Yang, JH Shieh, ... Journal of Experimental Medicine 208 (9), 1757-1765, 2011 | 33 | 2011 |
| Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R) DS Geller, J Morris, E Revskaya, M Kahn, W Zhang, S Piperdi, A Park, ... Nuclear medicine and biology 43 (12), 812-817, 2016 | 32 | 2016 |
| HER‐2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study S Gorlick, DA Barkauskas, M Krailo, S Piperdi, R Sowers, J Gill, D Geller, ... Pediatric Blood & Cancer 61 (9), 1558-1564, 2014 | 32 | 2014 |
| Variability in the reported management of pulmonary metastases in osteosarcoma O Bhattasali, AT Vo, M Roth, D Geller, RL Randall, R Gorlick, J Gill Cancer medicine 4 (4), 523-531, 2015 | 31 | 2015 |
| Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model Y Yang, R Yang, M Roth, S Piperdi, W Zhang, H Dorfman, P Rao, A Park, ... Genes & Cancer 8 (1-2), 484, 2017 | 29 | 2017 |
| Cell surface vimentin‐positive circulating tumor cell‐based relapse prediction in a long‐term longitudinal study of postremission neuroblastoma patients IS Batth, L Dao, A Satelli, A Mitra, S Yi, H Noh, H Li, Z Brownlee, S Zhou, ... International journal of cancer 147 (12), 3550-3559, 2020 | 24 | 2020 |
